

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HIGHLY SPECIALISED TECHNOLOGIES EVALUATION PROGRAMME

Equality impact assessment – Scoping

HST: human alpha 1-proteinase inhibitor for treating emphysema

The impact on equality has been assessed during this evaluation according to the principles of the NICE equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Stakeholders highlighted that there is disparity in access to treatment across Europe. This is not an equality issue that can be addressed in a highly specialised technologies evaluation.

Stakeholders also noted that alpha-1 antitrypsin deficiency will occur nearly exclusively in people with Caucasian family origins.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

The prevalence of this condition in populations with specific family origins is not expected to be an equality issue.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No changes to the scope are needed.

4. Have any additional stakeholders related to potential equality issues

been identified during the scoping process, and, if so, have changes to the matrix been made?
No.

Approved by Associate Director (name): ...Sheela Upadhyaya.....

Date: 25/03/2018